

BIONTECH

We are advancing a deep and broad portfolio of product candidates derived from our four drug classes focused on the treatment of cancer, infectious and rare diseases:

Oncology

Drug Class	Platform	Product Candidate	Indication (Targets)	Pre-clinical	Phase 1	Phase 2	Phase 3	Rights/Collaborator
mRNA	FixVac (fixed combination of shared cancer antigens)	BNT111	Advanced melanoma (Adjuvant & Metastatic)	██████████	██████████	██████████		Fully-owned
		BNT112	Prostate cancer	██████████	██████████			Fully-owned
		BNT113	HPV16+ head and neck cancer ¹	██████████	██████████	██████████		Fully-owned
		BNT115	Ovarian cancer ¹	██████████	██████████			Fully-owned
		BNT116	NSCLC	██████████	██████████			Fully-owned
	iNeST (patient specific cancer antigen therapy)	autogene cevumeran (BNT122)	1L melanoma	██████████	██████████	██████████		Genentech (global 50:50 profit/loss share)
			Adjuvant colorectal cancer	██████████	██████████	██████████		
	Intratumoral Immunotherapy	SAR441000 (BNT131)	Solid tumors (IL-12sc, IL-15sushi, GM-CSF, IFNα)	██████████	██████████			Sanofi (global profit/loss share)
	RiboMabs (mRNA-encoded antibodies)	BNT141	Multiple solid tumors	██████████				Fully-owned
BNT142		Multiple solid tumors (CD3+CLDN6)	██████████	██████████			Fully-owned	
RiboCytokines (mRNA-encoded cytokines)	BNT151	Multiple solid tumors (Optimized IL-2)	██████████	██████████			Fully-owned	
	BNT152, BNT153	Multiple solid tumors (IL-7, IL-2)	██████████	██████████			Fully-owned	
Cell Therapies	CAR-T Cells	BNT211	Multiple solid tumors (CLDN6)	██████████	██████████			Fully-owned
		BNT212	Pancreatic, other cancers (CLDN18.2)	██████████				Fully-owned
	Neoantigen-based T cell therapy	BNT221 (NEO-PTC-01)	Multiple solid tumors	██████████	██████████			Fully-owned
	TCRs	To be selected	All tumors	██████████				Fully-owned
Antibodies	Next-Gen CP ² Immunomodulators	GEN1046 (BNT311)	Multiple solid tumors (PD-L1×4-1BB)	██████████	██████████	██████████		Genmab (global 50:50 profit/loss share)
		GEN1042 (BNT312)	Multiple solid tumors (CD40×4-1BB)	██████████	██████████			
		GEN1053 (BNT313)	Multiple solid tumors (CD27)	██████████				
Targeted Cancer Antibodies	BNT321 (MVT-5873)	Pancreatic cancer (sLea)	██████████	██████████			Fully-owned	
SMIM ³	Toll-Like Receptor Binding	BNT411	Solid tumors (TLR7)	██████████	██████████			Fully-owned

Infectious Diseases

Drug Class	Product Candidate	Indication (Targets)	Pre-clinical	Phase 1	Phase 2	Phase 3	Commercial	Rights/Collaborator
mRNA	BNT162b2	COVID-19	██████████	██████████	██████████	██████████	██████████	Fosun Pharma (China), Pfizer (Global, except China)
	BNT161	Influenza	██████████	██████████	██████████	██████████		Pfizer
mRNA	Un-named program	Shingles	██████████					Pfizer
	BNT164	Tuberculosis ⁴	██████████					Bill & Melinda Gates Foundation
	BNT165	Malaria	██████████					Fully-owned
	Un-named program	HSV 2	██████████					Fully-owned
	Un-named program	HIV ⁴	██████████					Bill & Melinda Gates Foundation
	Undisclosed programs	Additional mRNA vaccine programs ⁵	██████████					Fully-owned
	Undisclosed programs	Precision antibacterials	██████████					Fully-owned

1 BNT113 and BNT115 are currently being studied in investigator-initiated Phase 1 trials

2 Checkpoint Inhibitor

3 Small Molecule Immunomodulators

4 Collaboration with Bill & Melinda Gates Foundation. BioNTech holds worldwide distribution rights except developing countries where BMG holds distribution rights

5 University of Pennsylvania collaboration